Cost-cutting generics and biosimilars stuck in legal limbo

Cost-cutting generics and biosimilars stuck in legal limbo

Source: 
MedCity News
snippet: 

Many believe that the biosimilar industry can address the issue of spiraling drug costs, but first it has to make it through a thicket of challenges.